$AMED
AMEDISYS INC Stock $amed

$amed Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000089626224000014 Filed on February 22, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$571.4M	$570.8M	$2.236B
YoY Change	2.7%	1.55%	0.59%
Cost Of Revenue	$321.5M	$321.4M	$1.246B
YoY Change	2.08%	1.66%	-1.18%
Gross Profit	$249.9M	$249.4M	$990.9M
YoY Change	3.47%	1.41%	1.97%
Gross Profit Margin	43.73%	43.69%	44.31%
Selling, General & Admin	$193.3M	$199.7M	$780.1M
YoY Change	-0.64%	3.24%	3.45%
% of Gross Profit	77.37%	80.08%	78.72%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$6.138M	$5.847M	$23.85M
YoY Change	7.8%	11.8%	-4.36%
% of Gross Profit	2.46%	2.34%	2.41%
Operating Expenses	$197.6M	$203.8M	$797.8M
YoY Change	-0.71%	2.61%	2.42%
Operating Profit	$52.29M	$45.53M	$156.4M
YoY Change	23.32%	-3.62%	-13.5%
Interest Expense	-$5.482M	-$6.022M	$31.27M
YoY Change	-172.93%	13.32%	40.7%
% of Operating Profit	-10.48%	-13.23%	20.0%
Other Income/Expense, Net	$1.090M	$1.211M	-$116.8M
YoY Change	-114.21%	193.93%	468.84%
Pretax Income	$27.23M	$29.20M	$39.62M
YoY Change	-21.56%	-29.36%	-75.27%
Income Tax	$12.63M	$10.18M	$50.60M
% Of Pretax Income	46.4%	34.86%	127.7%
Net Earnings	$14.40M	$19.32M	-$9.747M
YoY Change	-42.96%	-39.08%	-108.22%
Net Earnings / Revenue	2.52%	3.39%	-0.44%
Basic Earnings Per Share	$0.44		-$0.30
Diluted Earnings Per Share	$0.44	$0.59	-$0.30
COMMON SHARES
Basic Shares Outstanding	32.67M shares	32.63M shares	32.60M shares
Diluted Shares Outstanding	32.98M shares		32.60M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$108.2M	$126.5M	$126.5M
YoY Change	118.94%	211.91%	211.91%
Cash & Equivalents	$108.2M	$126.5M	$126.5M
Short-Term Investments
Other Short-Term Assets	$58.86M	$30.10M	$57.11M
YoY Change	149.59%	14.02%	45.56%
Inventory
Prepaid Expenses	$20.33M	$14.64M
Receivables	$359.4M	$313.4M	$313.4M
Other Receivables	$0.00	$6.800M	$0.00
Total Short-Term Assets	$526.4M	$496.9M	$496.9M
YoY Change	29.81%	27.76%	27.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$131.1M	$41.80M	$130.8M
YoY Change	293.1%	161.25%	10.01%
Goodwill	$1.245B	$1.245B
YoY Change	0.0%	-3.32%
Intangibles	$101.8M	$102.7M
YoY Change	1.85%	1.48%
Long-Term Investments	$67.00M	$66.10M	$66.10M
YoY Change	13.75%	9.26%	9.26%
Other Assets	$18.86M	$85.10M	$85.10M
YoY Change	-75.9%	6.64%	340.1%
Total Long-Term Assets	$1.563B	$1.563B	$1.563B
YoY Change	1.43%	-1.52%	-1.52%
TOTAL ASSETS
Total Short-Term Assets	$526.4M	$496.9M	$496.9M
Total Long-Term Assets	$1.563B	$1.563B	$1.563B
Total Assets	$2.090B	$2.060B	$2.060B
YoY Change	7.34%	4.25%	4.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$36.25M	$28.24M	$28.24M
YoY Change	-9.42%	-35.44%	-35.44%
Accrued Expenses	$305.4M	$140.0M	$303.2M
YoY Change	121.45%	1.89%	2.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$37.23M	$36.30M	$36.31M
YoY Change	38.41%	134.19%	134.34%
Total Short-Term Liabilities	$484.9M	$473.7M	$473.7M
YoY Change	37.33%	33.24%	33.24%
LONG-TERM LIABILITIES
Long-Term Debt	$356.1M	$361.9M	$361.9M
YoY Change	-4.59%	-13.71%	-13.72%
Other Long-Term Liabilities	$63.05M	$1.400M	$64.17M
YoY Change	1218.72%	-70.83%	-13.65%
Total Long-Term Liabilities	$419.1M	$363.3M	$426.0M
YoY Change	10.89%	-14.36%	-13.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$484.9M	$473.7M	$473.7M
Total Long-Term Liabilities	$419.1M	$363.3M	$426.0M
Total Liabilities	$1.002B	$940.4M	$993.7M
YoY Change	23.12%	8.13%	7.46%
SHAREHOLDERS EQUITY
Retained Earnings	$762.3M	$747.9M
YoY Change	-2.63%	-1.29%
Common Stock	$795.1M	$787.2M
YoY Change	4.8%	4.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$469.2M	$468.6M
YoY Change	1.46%	1.61%
Treasury Stock Shares
Shareholders Equity	$1.088B	$1.067B	$1.067B
YoY Change
Total Liabilities & Shareholders Equity	$2.090B	$2.060B	$2.060B
YoY Change	7.34%	4.25%	4.25%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$14.40M	$19.32M	-$9.747M
YoY Change	-42.96%	-39.08%	-108.22%
Depreciation, Depletion And Amortization	$6.138M	$5.847M	$23.85M
YoY Change	7.8%	11.8%	-4.36%
Cash From Operating Activities	-$6.541M	$60.29M	$137.2M
YoY Change	-125.2%	47.46%	2.93%
INVESTING ACTIVITIES
Capital Expenditures	$2.893M	$2.113M	$5.620M
YoY Change	114.3%	4.14%	-8.84%
Acquisitions	$0.00		$350.0K
YoY Change	-100.0%		-99.51%
Other Investing Activities	-$175.0K	$77.00K	$47.78M
YoY Change	-100.37%	-52.76%	-154.75%
Cash From Investing Activities	-$3.068M	-$2.036M	$35.06M
YoY Change	-106.68%	9.11%	-137.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net	$8.941M		$76.01M
YoY Change	-83.84%		471.7%
Cash From Financing Activities	-8.550M	-13.42M	-$87.52M
YoY Change	-84.97%	-17.88%	187.59%
NET CHANGE
Cash From Operating Activities	-6.541M	60.29M	$137.2M
Cash From Investing Activities	-3.068M	-2.036M	$35.06M
Cash From Financing Activities	-8.550M	-13.42M	-$87.52M
Net Change In Cash	-18.16M	44.83M	$84.73M
YoY Change	-221.33%	97.72%	913.03%
FREE CASH FLOW
Cash From Operating Activities	-$6.541M	$60.29M	$137.2M
Capital Expenditures	$2.893M	$2.113M	$5.620M
Free Cash Flow	-$9.434M	$58.17M	$131.6M
YoY Change	-138.33%	49.73%	3.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	-106000000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	50559000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42545000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-10936000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	210166000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1189000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-910000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1094000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	118609000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	209072000	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.41
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3009000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	2042427000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	1975497000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	180772000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	251915000	usd
CY2021	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	49000	usd
CY2021	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1747000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	13296000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	9143000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000896262
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	134267000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	62751000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	23377000	usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Entity Registrant Name EntityRegistrantName	AMEDISYS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-3131700
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3854 American Way, Suite A,
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	2600000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32667631	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126450000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40540000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	12413000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	13593000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	313373000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	296785000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14639000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11628000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	30060000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	26415000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	496935000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	388961000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	92422000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	101364000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41845000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16026000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	88939000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	102856000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1244679000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1287399000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14008000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14604000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	102675000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	101167000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	85097000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79836000	usd
CY2023Q4	us-gaap	Assets Assets	2060170000	usd
CY2022Q4	us-gaap	Assets Assets	1976245000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	28237000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	43735000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	136835000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	125387000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	140049000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	137390000	usd
CY2023Q4	amed	Termination Fee Payable TerminationFeePayable	106000000	usd
CY2022Q4	amed	Termination Fee Payable TerminationFeePayable	0	usd
CY2023Q4	us-gaap	Debt Current DebtCurrent	36314000	usd
CY2022Q4	us-gaap	Debt Current DebtCurrent	15496000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	26286000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	33521000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	473721000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	355529000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	361862000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	419420000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	62751000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	69504000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	40635000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	20411000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1418000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4808000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	940387000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	869672000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38131478	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37891186	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32667631	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32511465	shares
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	38000	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	38000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	787177000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	755063000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	5463847	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	5379721	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	468626000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	461200000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	747925000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	757672000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1066514000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1051573000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	53269000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	55000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1119783000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1106573000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2060170000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1976245000	usd
CY2023	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	2236382000	usd
CY2022	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	2223199000	usd
CY2021	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	2214112000	usd
CY2023	us-gaap	Other Operating Income OtherOperatingIncome	0	usd
CY2022	us-gaap	Other Operating Income OtherOperatingIncome	0	usd
CY2021	us-gaap	Other Operating Income OtherOperatingIncome	13300000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1245509000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1260425000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1233356000	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	516049000	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	508791000	usd
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	474718000	usd
CY2023	amed	Non Cash Compensation Excluding Merger Related Expenses NonCashCompensationExcludingMergerRelatedExpenses	26082000	usd
CY2022	amed	Non Cash Compensation Excluding Merger Related Expenses NonCashCompensationExcludingMergerRelatedExpenses	16560000	usd
CY2021	amed	Non Cash Compensation Excluding Merger Related Expenses NonCashCompensationExcludingMergerRelatedExpenses	23809000	usd
CY2023	amed	Merger Related Expenses MergerRelatedExpenses	36672000	usd
CY2022	amed	Merger Related Expenses MergerRelatedExpenses	0	usd
CY2021	amed	Merger Related Expenses MergerRelatedExpenses	0	usd
CY2023	amed	Depreciation And Amortization For Continuing Operations DepreciationAndAmortizationForContinuingOperations	17747000	usd
CY2022	amed	Depreciation And Amortization For Continuing Operations DepreciationAndAmortizationForContinuingOperations	24935000	usd
CY2021	amed	Depreciation And Amortization For Continuing Operations DepreciationAndAmortizationForContinuingOperations	30901000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	237929000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	228707000	usd
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	212713000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	2079988000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	31098000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	39623000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	117699000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9747000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.65
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32599000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32517000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32642000	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.63
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	6.34
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32599000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32653000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32972000	shares
CY2023	us-gaap	Profit Loss ProfitLoss	-10936000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	117699000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	210166000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-10936000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	117699000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	210166000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1189000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-910000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1094000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9747000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	118609000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	209072000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	810741000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3968000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2054000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23809000	usd
CY2021	amed	Surrendered Shares SurrenderedShares	-16898000	usd
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	99878000	usd
CY2021	amed	Contributions Attributable To Noncontrolling Interest ContributionsAttributableToNoncontrollingInterest	250000	usd
CY2021	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	43858000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	210166000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	976323000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3848000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2304000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16560000	usd
CY2022	amed	Surrendered Shares SurrenderedShares	-7981000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	17351000	usd
CY2022	amed	Contributions Attributable To Noncontrolling Interest ContributionsAttributableToNoncontrollingInterest	12401000	usd
CY2022	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1561000	usd
CY2022	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	4331000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	117699000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2602000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	100000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29024000	usd
CY2023	amed	Surrendered Shares SurrenderedShares	-6529000	usd
CY2023	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	-630000	usd
CY2023	amed	Contributions Attributable To Noncontrolling Interest ContributionsAttributableToNoncontrollingInterest	1452000	usd
CY2023	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1873000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-10936000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-10936000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	117699000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	210166000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23847000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24935000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	30901000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	29024000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	16560000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	23809000	usd
CY2023	amed	Amortization And Impairment Of Operating Lease Right Of Use Asset AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset	33996000	usd
CY2022	amed	Amortization And Impairment Of Operating Lease Right Of Use Asset AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset	46029000	usd
CY2021	amed	Amortization And Impairment Of Operating Lease Right Of Use Asset AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset	40364000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-319000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-519000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	124000	usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	usd
CY2021	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	31098000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	20655000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	23377000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	44582000	usd
CY2023	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-2186000	usd
CY2022	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2021	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2023	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	-106000000	usd
CY2022	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	usd
CY2021	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	10760000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-45000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	4949000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	991000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	991000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	917000	usd
CY2023	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	5073000	usd
CY2022	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	5163000	usd
CY2021	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	5343000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3009000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	26727000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14230000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	18030000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6638000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3525000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12202000	usd
CY2023	amed	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-3786000	usd
CY2022	amed	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-3242000	usd
CY2021	amed	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-3060000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-189000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-438000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-15816000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-26915000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-8822000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-28796000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-30733000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-41175000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-36645000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	137188000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	133283000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	188893000	usd
CY2023	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	54000	usd
CY2022	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	252000	usd
CY2021	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	135000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	136000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	66000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	144000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5620000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6165000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6302000	usd
CY2023	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	7093000	usd
CY2022	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	1050000	usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	637000	usd
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	200000	usd
CY2023	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	usd
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	15000000	usd
CY2021	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	5000000	usd
CY2023	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	150000	usd
CY2022	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	usd
CY2021	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	usd
CY2023	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	47787000	usd
CY2022	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	usd
CY2021	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	350000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	71952000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	269965000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	35064000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-94486000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-281607000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2304000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2054000	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2602000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3848000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3968000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	6529000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7981000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16898000	usd
CY2023	amed	Cash Contribution To Noncontrolling Interest CashContributionToNoncontrollingInterest	1452000	usd
CY2022	amed	Cash Contribution To Noncontrolling Interest CashContributionToNoncontrollingInterest	3501000	usd
CY2021	amed	Cash Contribution To Noncontrolling Interest CashContributionToNoncontrollingInterest	250000	usd
CY2023	amed	Cash Distribution To Noncontrolling Interest CashDistributionToNoncontrollingInterest	1873000	usd
CY2022	amed	Cash Distribution To Noncontrolling Interest CashDistributionToNoncontrollingInterest	1561000	usd
CY2021	amed	Cash Distribution To Noncontrolling Interest CashDistributionToNoncontrollingInterest	1747000	usd
CY2023	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2022	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	5817000	usd
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2023	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	800000	usd
CY2022	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0	usd
CY2021	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0	usd
CY2023	amed	Proceeds From Borrowings Under Term Loan ProceedsFromBorrowingsUnderTermLoan	0	usd
CY2022	amed	Proceeds From Borrowings Under Term Loan ProceedsFromBorrowingsUnderTermLoan	0	usd
CY2021	amed	Proceeds From Borrowings Under Term Loan ProceedsFromBorrowingsUnderTermLoan	290312000	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	23000000	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	534500000	usd
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	500700000	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	23000000	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	534500000	usd
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	551700000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	76013000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2792000	usd
CY2023	amed	Funds Received From Provider Relief Fund Advance FundsReceivedFromProviderReliefFundAdvance	0	usd
CY2022	amed	Funds Received From Provider Relief Fund Advance FundsReceivedFromProviderReliefFundAdvance	0	usd
CY2021	amed	Funds Received From Provider Relief Fund Advance FundsReceivedFromProviderReliefFundAdvance	-60000000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	17351000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	99878000	usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	6461000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	5714000	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-87522000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-30433000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55126000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	84730000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	8364000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-37588000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54133000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45769000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83357000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138863000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54133000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45769000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	29766000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	14939000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	5291000	usd
CY2023	amed	Cash Paid For Infinity Zpic Interest CashPaidForInfinityZPICInterest	0	usd
CY2022	amed	Cash Paid For Infinity Zpic Interest CashPaidForInfinityZPICInterest	12755000	usd
CY2021	amed	Cash Paid For Infinity Zpic Interest CashPaidForInfinityZPICInterest	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	29127000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	24013000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	34097000	usd
CY2023	amed	Non Cash Accrued Contingent Consideration NonCashAccruedContingentConsideration	0	usd
CY2022	amed	Non Cash Accrued Contingent Consideration NonCashAccruedContingentConsideration	19195000	usd
CY2021	amed	Non Cash Accrued Contingent Consideration NonCashAccruedContingentConsideration	0	usd
CY2023	amed	Non Cash Noncontrolling Interest Contribution NonCashNoncontrollingInterestContribution	0	usd
CY2022	amed	Non Cash Noncontrolling Interest Contribution NonCashNoncontrollingInterestContribution	8900000	usd
CY2021	amed	Non Cash Noncontrolling Interest Contribution NonCashNoncontrollingInterestContribution	0	usd
CY2023Q4	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	37	state
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. The Company's critical accounting estimates include revenue recognition and testing for the impairment of goodwill and other intangible assets. Actual results could materially differ from those estimates.</span></div>
CY2023	amed	Revenuebypayorclassasapercentageoftotalnetservicerevenue Revenuebypayorclassasapercentageoftotalnetservicerevenue	1
CY2022	amed	Revenuebypayorclassasapercentageoftotalnetservicerevenue Revenuebypayorclassasapercentageoftotalnetservicerevenue	1
CY2021	amed	Revenuebypayorclassasapercentageoftotalnetservicerevenue Revenuebypayorclassasapercentageoftotalnetservicerevenue	1
CY2023	amed	Net Service Revenue Episode Payment Rate Duration NetServiceRevenueEpisodePaymentRateDuration	P60D
CY2023	amed	Net Service Revenue Period Of Care Payment Rate Duration NetServiceRevenuePeriodOfCarePaymentRateDuration	P30D
CY2023	amed	Net Service Revenue Period Of Care Payment Rate Duration NetServiceRevenuePeriodOfCarePaymentRateDuration	P30D
CY2023	amed	Net Service Revenue Period Of Care Payment Rate Duration NetServiceRevenuePeriodOfCarePaymentRateDuration	P30D
CY2023	amed	Net Service Revenue Period Of Care Payment Rate Duration NetServiceRevenuePeriodOfCarePaymentRateDuration	P30D
CY2023	amed	Percentage Of Total Reimbursement Of Outlier Payment PercentageOfTotalReimbursementOfOutlierPayment	0.10
CY2023	amed	Net Service Revenue Period Of Care Payment Rate Duration NetServiceRevenuePeriodOfCarePaymentRateDuration	P30D
CY2022	amed	Hospice Medicare Revenue Rate Accounted For Routine Care HospiceMedicareRevenueRateAccountedForRoutineCare	0.97
CY2023	amed	Hospice Medicare Revenue Rate Accounted For Routine Care HospiceMedicareRevenueRateAccountedForRoutineCare	0.97
CY2021	amed	Hospice Medicare Revenue Rate Accounted For Routine Care HospiceMedicareRevenueRateAccountedForRoutineCare	0.97
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126500000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40500000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	12400000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	13600000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138900000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54100000	usd
CY2023	amed	Percentage Of Patient Receivables Outstanding PercentageOfPatientReceivablesOutstanding	0.10
CY2023	amed	Portion Of Patient Accounts Receivable Derived From Medicare PortionOfPatientAccountsReceivableDerivedFromMedicare	0.69
CY2022	amed	Portion Of Patient Accounts Receivable Derived From Medicare PortionOfPatientAccountsReceivableDerivedFromMedicare	0.67
CY2023	amed	Historical Collection Rate From Medicare HistoricalCollectionRateFromMedicare	0.99
CY2023	amed	Net Service Revenue Period Of Care Payment Rate Duration NetServiceRevenuePeriodOfCarePaymentRateDuration	P30D
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	117400000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	92400000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	101400000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41800000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16000000.0	usd
CY2023	us-gaap	Depreciation Depreciation	18200000	usd
CY2022	us-gaap	Depreciation Depreciation	11500000	usd
CY2021	us-gaap	Depreciation Depreciation	12100000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1244700000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	102700000	usd
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2600000	usd
CY2023	amed	Unamortized Debt Issuance Cost Amortization Period UnamortizedDebtIssuanceCostAmortizationPeriod	P2Y7M6D
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13500000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	101200000	usd
CY2023	amed	Other Intangible Assets Additions OtherIntangibleAssetsAdditions	7200000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5700000	usd
CY2023Q4	amed	Debt Instrument Carrying Amount Excluding Finance Leases DebtInstrumentCarryingAmountExcludingFinanceLeases	371900000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	29000000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	16600000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	23800000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	7500000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	4300000	usd
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	6000000	usd
CY2023Q4	amed	Reduction To Income Tax Benefit Recognized Per162m ReductionToIncomeTaxBenefitRecognizedPer162m	2700000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32599000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32517000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32642000	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	39000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	122000	shares
CY2023	amed	Non Vested Stock And Stock Units NonVestedStockAndStockUnits	0	shares
CY2022	amed	Non Vested Stock And Stock Units NonVestedStockAndStockUnits	97000	shares
CY2021	amed	Non Vested Stock And Stock Units NonVestedStockAndStockUnits	208000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32599000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32653000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32972000	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	619000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	303000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	114000	shares
CY2023	us-gaap	Advertising Expense AdvertisingExpense	7200000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	7300000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	7400000	usd
CY2023Q4	amed	Minimum Percent Ownership For Controlling Interest Percent MinimumPercentOwnershipForControllingInterestPercent	0.50
CY2023Q4	amed	Maximum Percent Ownership For Equity Method Percent MaximumPercentOwnershipForEquityMethodPercent	0.50
CY2023Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	46100000	usd
CY2022Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	40500000	usd
CY2023Q4	amed	Maximum Percent Ownership For Cost Method Percent MaximumPercentOwnershipForCostMethodPercent	0.20
CY2023Q4	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	20000000	usd
CY2022Q4	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	20000000	usd
CY2020Q1	amed	Funding For Healthcare Providers Including Hospitals FundingForHealthcareProvidersIncludingHospitals	175000000000	usd
CY2020Q1	amed	Funding Immediately Distributed To Healthcare Providers Based On Their2019 Medicare Fee For Service Reimbursements FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements	30000000000	usd
CY2020Q2	amed	Funding Received From Cares Act FundingReceivedFromCARESAct	100000000	usd
CY2020Q1	amed	Funding Immediately Distributed To Healthcare Providers Based On Their2019 Medicare Fee For Service Reimbursements FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements	30000000000	usd
	amed	Cares Act Provider Relief Funds Utilized CARESActProviderReliefFundsUtilized	46600000	usd
CY2021Q4	amed	Cares Act Interest Repaid To Government CARESActInterestRepaidToGovernment	200000	usd
CY2021Q4	amed	Cares Act Provider Relief Funds Repaid To The Government CARESActProviderReliefFundsRepaidToTheGovernment	58300000	usd
	amed	Cares Act Provider Relief Fund Utilized By Unconsolidated Joint Ventures CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures	1300000	usd
CY2021Q4	amed	Cares Act Provider Relief Funds Repaid By Unconsolidated Joint Ventures CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures	600000	usd
CY2020Q4	amed	Total Cares Act Provider Relief Funds Received TotalCARESActProviderReliefFundsReceived	106800000	usd
CY2022	amed	Extension Of Temporary Suspension Of Sequestration Revenue Impact ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact	13000000	usd
CY2021	amed	Extension Of Temporary Suspension Of Sequestration Revenue Impact ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact	36000000	usd
CY2023Q4	amed	Termination Fee Payable TerminationFeePayable	106000000	usd
CY2023Q4	amed	Termination Fee Payable TerminationFeePayable	106000000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	1196100000	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	94100000	usd
CY2022	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-2800000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1287400000	usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	300000	usd
CY2023	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	200000	usd
CY2023	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	0	usd
CY2023	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	-43100000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1244700000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	111200000	usd
CY2022	amed	Other Intangible Assets Additions OtherIntangibleAssetsAdditions	3500000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	102700000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4500000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4500000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4500000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4500000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2400000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20400000	usd
CY2023Q4	amed	Payroll Tax Escrow PayrollTaxEscrow	7000000.0	usd
CY2022Q4	amed	Payroll Tax Escrow PayrollTaxEscrow	7600000	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	8000000.0	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	8800000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	6800000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3600000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	8300000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	6400000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	30100000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	26400000	usd
CY2023Q4	amed	Workers Compensation Deposits WorkersCompensationDeposits	200000	usd
CY2022Q4	amed	Workers Compensation Deposits WorkersCompensationDeposits	300000	usd
CY2023Q4	amed	Health Insurance Deposits HealthInsuranceDeposits	1500000	usd
CY2022Q4	amed	Health Insurance Deposits HealthInsuranceDeposits	900000	usd
CY2023Q4	amed	Other Miscellaneous Deposits OtherMiscellaneousDeposits	1000000.0	usd
CY2022Q4	amed	Other Miscellaneous Deposits OtherMiscellaneousDeposits	1000000.0	usd
CY2023Q4	us-gaap	Loss Contingency Receivable Noncurrent LossContingencyReceivableNoncurrent	13600000	usd
CY2022Q4	us-gaap	Loss Contingency Receivable Noncurrent LossContingencyReceivableNoncurrent	13600000	usd
CY2023Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	46100000	usd
CY2022Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	40500000	usd
CY2023Q4	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	20000000.0	usd
CY2022Q4	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	20000000.0	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	2700000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	3500000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	85100000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79800000	usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	18200000	usd
CY2022Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	16200000	usd
CY2023Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	41800000	usd
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	40600000	usd
CY2023Q4	amed	Legal And Other Settlements LegalAndOtherSettlements	24600000	usd
CY2022Q4	amed	Legal And Other Settlements LegalAndOtherSettlements	29900000	usd
CY2023Q4	amed	Charity Care CharityCare	2700000	usd
CY2022Q4	amed	Charity Care CharityCare	1900000	usd
CY2023Q4	amed	Estimated Medicare Cap Liability EstimatedMedicareCapLiability	2300000	usd
CY2022Q4	amed	Estimated Medicare Cap Liability EstimatedMedicareCapLiability	4300000	usd
CY2023Q4	amed	Hospice Accruals HospiceAccruals	23300000	usd
CY2022Q4	amed	Hospice Accruals HospiceAccruals	19100000	usd
CY2023Q4	amed	Patient Liability PatientLiability	15100000	usd
CY2022Q4	amed	Patient Liability PatientLiability	8900000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	7100000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	10500000	usd
CY2023Q4	amed	Accrued Interest AccruedInterest	1100000	usd
CY2022Q4	amed	Accrued Interest AccruedInterest	200000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3800000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5800000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	140000000.0	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	137400000	usd
CY2023Q4	amed	Deferred Compensation Plan Liability DeferredCompensationPlanLiability	600000	usd
CY2022Q4	amed	Deferred Compensation Plan Liability DeferredCompensationPlanLiability	600000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3200000	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	800000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	1000000.0	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1400000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4800000	usd
CY2023Q1	amed	Reclassification Of Operating Lease To Finance Lease ReclassificationOfOperatingLeaseToFinanceLease	15000000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	33800000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	43900000	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	200000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	2100000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	34000000.0	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	46000000.0	usd
CY2023	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	usd
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	500000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5800000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1800000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1600000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	100000	usd
CY2023	amed	Finance Lease Cost FinanceLeaseCost	7400000	usd
CY2022	amed	Finance Lease Cost FinanceLeaseCost	2400000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	3700000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	3400000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023	us-gaap	Lease Cost LeaseCost	45100000	usd
CY2022	us-gaap	Lease Cost LeaseCost	51800000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	88900000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	102900000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	26300000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	33500000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	69500000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	89000000.0	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	103000000.0	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	39800000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	4100000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	11200000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	1800000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	34500000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	44400000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	11600000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1500000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	33900000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	45100000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	40000000.0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	2100000	usd
CY2023	amed	Lessee Operating Lease Reductions To Rou Assets Resulting From Reductions To Lease Obligations LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations	-15200000	usd
CY2022	amed	Lessee Operating Lease Reductions To Rou Assets Resulting From Reductions To Lease Obligations LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations	-4200000	usd
CY2023	amed	Lessee Finance Lease Reduction To Rou Assets Resulting From Reductions To Lease Obligations LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations	-1700000	usd
CY2022	amed	Lessee Finance Lease Reduction To Rou Assets Resulting From Reductions To Lease Obligations LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations	-600000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3500000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	398200000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	434900000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	36300000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	15500000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.042
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.034
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.066
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.053
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	29500000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	14700000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	26100000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	10900000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	19700000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	3700000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	13200000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	900000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7100000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	900000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1200000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	400000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	96800000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	31500000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7800000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	2600000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	89000000.0	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	400800000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	438400000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2600000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	361900000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	419400000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	36300000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	32300000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	330000000.0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	900000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	900000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	400000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	400800000	usd
CY2023Q4	amed	Total Leverage Ratio TotalLeverageRatio	2.3
CY2023Q4	amed	Consolidated Interest Coverage Ratio ConsolidatedInterestCoverageRatio	4.9
CY2023Q1	amed	Reclassification Of Operating Lease To Finance Lease ReclassificationOfOperatingLeaseToFinanceLease	15000000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	21100000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	12200000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	20300000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8800000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000000.0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5200000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	29900000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	19200000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	25500000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	17500000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	20400000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	35900000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	3200000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	2900000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	8700000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	20700000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	44600000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	50600000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42500000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	70100000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	50600000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42500000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	70100000	usd
CY2023	amed	Income Tax Effects Allocated To Interest Expense IncomeTaxEffectsAllocatedToInterestExpense	0	usd
CY2022	amed	Income Tax Effects Allocated To Interest Expense IncomeTaxEffectsAllocatedToInterestExpense	-700000	usd
CY2021	amed	Income Tax Effects Allocated To Interest Expense IncomeTaxEffectsAllocatedToInterestExpense	100000	usd
CY2023	amed	Income Tax Effects Allocated To Goodwill IncomeTaxEffectsAllocatedToGoodwill	-300000	usd
CY2022	amed	Income Tax Effects Allocated To Goodwill IncomeTaxEffectsAllocatedToGoodwill	-2700000	usd
CY2021	amed	Income Tax Effects Allocated To Goodwill IncomeTaxEffectsAllocatedToGoodwill	3100000	usd
CY2023	amed	Tax Expense Recorded To Additional Paid In Capital TaxExpenseRecordedToAdditionalPaidInCapital	-200000	usd
CY2022	amed	Tax Expense Recorded To Additional Paid In Capital TaxExpenseRecordedToAdditionalPaidInCapital	1500000	usd
CY2021	amed	Tax Expense Recorded To Additional Paid In Capital TaxExpenseRecordedToAdditionalPaidInCapital	0	usd
CY2023	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	50100000	usd
CY2022	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	40600000	usd
CY2021	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	73300000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.260
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.056
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.050
CY2023	amed	Effective Income Tax Rate Reconciliation Excess Tax Benefit Sharebased Compensation Percent EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent	-0.034
CY2022	amed	Effective Income Tax Rate Reconciliation Excess Tax Benefit Sharebased Compensation Percent EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent	-0.003
CY2021	amed	Effective Income Tax Rate Reconciliation Excess Tax Benefit Sharebased Compensation Percent EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent	0.021
CY2023	amed	Effective Income Tax Rate Reconciliation Non Deductible Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent	0.055
CY2022	amed	Effective Income Tax Rate Reconciliation Non Deductible Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent	0.008
CY2021	amed	Effective Income Tax Rate Reconciliation Non Deductible Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent	0.012
CY2023	amed	Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits Percent EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent	0
CY2022	amed	Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits Percent EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent	-0.017
CY2021	amed	Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits Percent EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent	0
CY2023	amed	Effective Income Tax Rate Reconciliation Merger Related Expenses Percent EffectiveIncomeTaxRateReconciliationMergerRelatedExpensesPercent	0.137
CY2022	amed	Effective Income Tax Rate Reconciliation Merger Related Expenses Percent EffectiveIncomeTaxRateReconciliationMergerRelatedExpensesPercent	0
CY2021	amed	Effective Income Tax Rate Reconciliation Merger Related Expenses Percent EffectiveIncomeTaxRateReconciliationMergerRelatedExpensesPercent	0
CY2023	amed	Effective Income Tax Rate Reconciliation Merger Termination Fee Percent EffectiveIncomeTaxRateReconciliationMergerTerminationFeePercent	0.562
CY2022	amed	Effective Income Tax Rate Reconciliation Merger Termination Fee Percent EffectiveIncomeTaxRateReconciliationMergerTerminationFeePercent	0
CY2021	amed	Effective Income Tax Rate Reconciliation Merger Termination Fee Percent EffectiveIncomeTaxRateReconciliationMergerTerminationFeePercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.019
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.001
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.277
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.265
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.250
CY2023	amed	Merger Related Expenses MergerRelatedExpenses	36700000	usd
CY2023	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	-106000000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2700000	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	8000000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	8800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	17100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	14100000	usd
CY2023Q4	amed	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Workers Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation	10900000	usd
CY2022Q4	amed	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Workers Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation	10600000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5700000	usd
CY2023Q4	amed	Deferred Tax Assets Legal And Compliance Matters DeferredTaxAssetsLegalAndComplianceMatters	3900000	usd
CY2022Q4	amed	Deferred Tax Assets Legal And Compliance Matters DeferredTaxAssetsLegalAndComplianceMatters	4700000	usd
CY2023Q4	amed	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	25600000	usd
CY2022Q4	amed	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	27800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	8900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	11600000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2900000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	200000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	200000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	76400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	77600000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5200000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	71000000.0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	72400000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	13500000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6600000	usd
CY2023Q4	amed	Deferred Tax Liabilities Amortization Of Intangible Assets DeferredTaxLiabilitiesAmortizationOfIntangibleAssets	61700000	usd
CY2022Q4	amed	Deferred Tax Liabilities Amortization Of Intangible Assets DeferredTaxLiabilitiesAmortizationOfIntangibleAssets	48500000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	10800000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	10000000.0	usd
CY2023Q4	amed	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	24900000	usd
CY2022Q4	amed	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	27000000.0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	700000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	700000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	111600000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	92800000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	40600000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	20400000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	8100000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5200000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	200000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1900000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	200000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2700000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2700000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2700000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2700000	usd
CY2022Q4	amed	Recognized Tax Benefit That Impacts Effective Tax Rate RecognizedTaxBenefitThatImpactsEffectiveTaxRate	2700000	usd
CY2022	amed	Benefit As Component Of Interest Expense BenefitAsComponentOfInterestExpense	700000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38131478	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32667631	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023	amed	Percentageofownershipinsubsidiaries Percentageofownershipinsubsidiaries	0.50
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2500000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1200000	shares
CY2023	amed	Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries	0.10
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Purchase Date ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate	0.85
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	3195155	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	18.98
CY2022Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	6184	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	146.45
CY2022Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	10814	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	89.35
CY2022Q3	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	12047	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	82.27
CY2022Q4	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	11498	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	71.01
CY2023Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	14995	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	62.52
CY2023Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	10915	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	77.72
CY2023Q3	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	0
CY2023Q4	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	0
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	3261608	shares
CY2023	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	300000	usd
CY2022	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	700000	usd
CY2021	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	700000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	218612	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	142.86
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M21D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	55280	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	84.48
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	12933	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	77.05
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	15621	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	179.84
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	245338	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	130.82
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M8D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	173319	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	129.05
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M15D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	55326	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	83.79
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	55280	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	39.70
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	34810	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	65.66
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	3777	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	86.69
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	72019	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	58.56
CY2023	amed	Performance Based Objective Satisfied Percentage PerformanceBasedObjectiveSatisfiedPercentage	1.2723
CY2023	amed	Health Insurance HealthInsurance	18200000	usd
CY2022	amed	Health Insurance HealthInsurance	16200000	usd
CY2023	amed	Wokers Compensation WokersCompensation	42000000.0	usd
CY2022	amed	Wokers Compensation WokersCompensation	40800000	usd
CY2023	amed	Professional Liability ProfessionalLiability	5400000	usd
CY2022	amed	Professional Liability ProfessionalLiability	5000000.0	usd
CY2023	amed	Estimated Insurance Total EstimatedInsuranceTotal	65600000	usd
CY2022	amed	Estimated Insurance Total EstimatedInsuranceTotal	62000000.0	usd
CY2023	amed	Estimated Insurance Long Term Portion EstimatedInsuranceLongTermPortion	200000	usd
CY2022	amed	Estimated Insurance Long Term Portion EstimatedInsuranceLongTermPortion	200000	usd
CY2023	amed	Estimated Insurance Excluding Long Term Portion EstimatedInsuranceExcludingLongTermPortion	65400000	usd
CY2022	amed	Estimated Insurance Excluding Long Term Portion EstimatedInsuranceExcludingLongTermPortion	61800000	usd
CY2023	amed	Health Insurance Retention Limit HealthInsuranceRetentionLimit	1300000	usd
CY2023	amed	Workers Compensation Insurance Retention Limit WorkersCompensationInsuranceRetentionLimit	2000000	usd
CY2023	amed	Professional Liability Insurance Retention Limit ProfessionalLiabilityInsuranceRetentionLimit	300000	usd
CY2023	amed	Fleet Insurance Exposure Limit FleetInsuranceExposureLimit	400000	usd
CY2023	amed	Defined Contribution Plan Employer Matching Contribution DefinedContributionPlanEmployerMatchingContribution	0.44	usd
CY2023	amed	Defined Contribution Plan Employee Contribution For Employee Matching Program DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram	1.00	usd
CY2023	amed	Defind Contribution Plan Maximum Annual Match Per Employee Salary Percentage DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage	0.06
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	20400000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	18600000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	17000000	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	2236400000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1245500000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	816800000	usd
CY2023	amed	Depreciation And Amortization For Continuing Operations DepreciationAndAmortizationForContinuingOperations	17700000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	2080000000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	156400000	usd
CY2023	amed	Merger Related Expenses MergerRelatedExpenses	36700000	usd
CY2022	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	2223200000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1260400000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	754100000	usd
CY2022	amed	Depreciation And Amortization For Continuing Operations DepreciationAndAmortizationForContinuingOperations	24900000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3000000.0	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	2042400000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	180800000	usd
CY2021	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	2214100000	usd
CY2021	us-gaap	Other Operating Income OtherOperatingIncome	13300000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1233400000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	711200000	usd
CY2021	amed	Depreciation And Amortization For Continuing Operations DepreciationAndAmortizationForContinuingOperations	30900000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	1975500000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	251900000	usd
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	Baton Rouge, Louisiana
CY2023	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0000896262-24-000014-index-headers.html	Edgar Link	pending
0000896262-24-000014-index.html	Edgar Link	pending
0000896262-24-000014.txt	Edgar Link	pending
0000896262-24-000014-xbrl.zip	Edgar Link	pending
a202310-kexhibit211.htm	Edgar Link	pending
a202310-kexhibit231.htm	Edgar Link	pending
a202310-kexhibit311.htm	Edgar Link	pending
a202310-kexhibit312.htm	Edgar Link	pending
a202310-kexhibit321.htm	Edgar Link	pending
a202310-kexhibit322.htm	Edgar Link	pending
a202310-kexhibit971.htm	Edgar Link	pending
amed-20231231.htm	Edgar Link	pending
amed-20231231.xsd	Edgar Link	pending
amed-20231231_g1.jpg	Edgar Link	pending
amed-20231231_g2.jpg	Edgar Link	pending
amedexhibit1033.htm	Edgar Link	pending
amedexhibit1034.htm	Edgar Link	pending
exhibit1031amedspecialtime.htm	Edgar Link	pending
exhibit1032amedspecialtime.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
amed-20231231_def.xml	Edgar Link	unprocessable
amed-20231231_lab.xml	Edgar Link	unprocessable
amed-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
amed-20231231_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
amed-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMED
AMEDISYS INC Stock $amed

2024 Q1 Form 10-K Financial Statement

#000089626224000014 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMED AMEDISYS INC Stock $amed

2024 Q1 Form 10-K Financial Statement

#000089626224000014 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMED
AMEDISYS INC Stock $amed